Last updated: February 13, 2026
What Is the Current Market Status of NDC 60505-2522?
NDC 60505-2522 corresponds to a specific branded or generic drug product. Based on available data, this NDC is associated with Mylotarg (gemtuzumab ozogamicin), a targeted therapy indicated for acute myeloid leukemia (AML). The product was originally approved in 2017 by the FDA, with a recall issued in 2010, later revised and re-approved in 2017.
The drug’s market landscape is influenced by its indication, competition, and recent regulatory changes. The notable dimensions for understanding its market include:
- Market Size: AML treatment market estimated at approximately $1.5 billion globally (IQVIA data, 2022). Mylotarg holds a niche within this, targeting relapsed or refractory AML.
- Competing Drugs: Include Vyxeos (daunorubicin and cytarabine), AML standard chemotherapies, and novel immunotherapies.
- Pricing Data: As of 2022, the wholesale acquisition cost (WAC) for Mylotarg was approximately $11,704 per vial, with typical dosing regimens resulting in a therapy cost of roughly $30,000–$35,000 per treatment course.
What Are the Price Trends for NDC 60505-2522?
Pricing for Mylotarg has experienced fluctuations influenced by FDA re-approvals, market competition, and patent status:
- Pre-2017: The drug was withdrawn in 2010 due to concerns over toxicity, with a significant reduction in sales.
- Post-2017 re-approval: The drug regained FDA approval with a new dosing regimen, leading to a price increase from previously lower levels.
- 2022 Data: The average wholesale price (AWP) for Mylotarg hovered around $11,700 per vial, with total treatment costs approximating $30,000–$35,000 per course, contingent on dosing specifics.
- Insurance Coverage & Negotiated Prices: Payers often negotiate discounts, leading to net prices potentially 30–50% lower than WAC.
What Are Future Price Projections?
Forecasting prices involves multiple factors:
| Factor |
Impact on Price |
| Patent & Exclusivity |
Patent expiry may prompt generic entry, reducing prices |
| Competition from Biosimilars |
Likely to drive prices downward within 3–5 years of biosimilar approval |
| Regulatory Changes |
Additional revisions or indications may increase pricing stability |
| Manufacturing & Supply Chain |
Increased costs could limit downward pressure in the short term |
Based on current trends, price reductions of 20–30% are anticipated over the next 3–5 years as generic or biosimilar versions enter the market. Market analysts project a decline to roughly $8,000–$10,000 per vial by 2026–2028, assuming biosimilar approval and adoption.
What Is the Outlook for Market Expansion?
Market penetration is driven by:
- Regulatory Approvals: Expansion into additional AML indications could extend the product lifecycle.
- Pricing Strategies: Price negotiations and managed access agreements impact net revenue.
- Development Pipeline: Companion diagnostics and improved formulations may sustain demand.
Despite these factors, the niche AML segment is limited in size; the drug’s growth is primarily tied to its positioning relative to upcoming competitors.
Summary of Key Data Points
| Aspect |
Data |
| Current Price (2022) |
~$11,700 per vial (WAC) |
| Per Course Cost |
~$30,000–$35,000 (variable by dose and patient weight) |
| Market Size |
~$1.5 billion globally (2022 estimates for AML market) |
| Competitive Licence & Biosimilar Timeline |
Biosimilar variants expected by 2025–2028, potentially reducing prices |
| Projected Price Drop |
20–30% over next 3–5 years |
What Are the Key Risks and Opportunities?
Risks:
- Patent expiration leading to biosimilar competition.
- Adverse safety profiles impacting reimbursement.
- Regulatory delays for new indications or formulations.
Opportunities:
- New indications expanding market size.
- Development of biosimilars reducing costs.
- Improved clinical outcomes boosting utilization.
Key Takeaways
- NDC 60505-2522 (Mylotarg) currently has a wholesale price near $11,700 per vial.
- The treatment cost per course is approximately $30,000–$35,000.
- Market projections indicate a 20–30% price decline over 3–5 years due to biosimilar competition.
- The market size remains niche, focused on AML, with limited growth potential absent new indications.
- Strategic pricing and pipeline development influence long-term market positioning.
FAQs
-
When is a biosimilar for NDC 60505-2522 expected to launch?
Biosimilar approvals are projected between 2024 and 2028, depending on regulatory pathways and developer progress.
-
How does the price of NDC 60505-2522 compare to competitors?
Its current price is comparable within the targeted AML therapy segment but may be supplanted by less expensive biosimilars upon entry.
-
What factors will influence the drug’s future pricing?
Patent status, biosimilar competition, regulatory updates, and payer negotiations play critical roles.
-
Is the current market for NDC 60505-2522 expected to grow?
Growth depends on expanded indications, but overall market size remains limited due to the specific AML focus.
-
What potential impact do regulatory changes have on pricing?
Changes encouraging biosimilar entry or favoring new formulations could lower costs and alter market dynamics.
Citations
- IQVIA, "Global Hematology & Oncology Market Report," 2022.
- FDA, "Approval history of gemtuzumab ozogamicin," 2017.
- Red Book Online, "Wholesale Acquisition Cost (WAC) Data," 2022.
